LIXT - Lixte Biotechnology Holdings, Inc. Stock Price, Fair Value and News

$1.66+0.14 (+9.21%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LIXT Price Action

Last 7 days

2.5%

Last 30 days

-13.5%

Last 90 days

-7.8%

Trailing 12 Months

-44.3%

LIXT RSI Chart

LIXT Valuation

Market Cap

3.7M

Price/Earnings (Trailing)

-0.93

Price/Sales (Trailing)

18.56

Price/Free Cashflow

-1.08

LIXT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LIXT Fundamentals

LIXT Revenue

Revenue (TTM)

200.0K

Rev. Growth (Yr)

-75.26%

Rev. Growth (Qtr)

-43.2%

LIXT Earnings

Earnings (TTM)

-4.0M

Earnings Growth (Yr)

3.21%

Earnings Growth (Qtr)

2.46%

LIXT Profitability

Return on Equity

-292.66%

Return on Assets

-235.9%

Free Cashflow Yield

-92.88%

LIXT Investor Care

Diluted EPS (TTM)

-1.7

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	200.0K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

CEO	Dr. John S. Kovach M.D.
WEBSITE	https://lixte.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	3

Lixte Biotechnology Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Lixte Biotechnology Holdings, Inc.? What does LIXT stand for in stocks?

LIXT is the stock ticker symbol of Lixte Biotechnology Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lixte Biotechnology Holdings, Inc. (LIXT)?

As of Fri Nov 22 2024, market cap of Lixte Biotechnology Holdings, Inc. is 3.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIXT stock?

You can check LIXT's fair value in chart for subscribers.

Is Lixte Biotechnology Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether LIXT is over valued or under valued. Whether Lixte Biotechnology Holdings, Inc. is cheap or expensive depends on the assumptions which impact Lixte Biotechnology Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIXT.

What is Lixte Biotechnology Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, LIXT's PE ratio (Price to Earnings) is -0.93 and Price to Sales (PS) ratio is 18.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIXT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lixte Biotechnology Holdings, Inc.'s stock?

In the past 10 years, Lixte Biotechnology Holdings, Inc. has provided -0.22 (multiply by 100 for percentage) rate of return.